No Data
No Data
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Largest Shareholders Are Individual Investors With 50% Ownership, Insiders Own 39%
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a
Express News | DiaMedica Therapeutics Files For Resale Of Up To 4.7M Common Shares By The Selling Shareholders
Express News | DiaMedica Therapeutics Inc Files for Resale of up to 4.7 Mln Common Shares by the Selling Shareholders - SEC Filing
Express News | DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $DiaMedica Therapeutics(DMAC.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.7% and a total average return of